



Verification Record — Retatrutide 30 mg

DRAFT / QA HOLD

SAMPLE INFORMATION

AnalytiLabs Code	AL-VR-RETATRUTIDE-30MG-20260502-005
Verification Key	BLV-RTA30-20260502-5C56D451
Record Scope	Documentation verification
Requestor	Document Control
Sample	Retatrutide 30 mg
Batch / Lot	Pending final lot confirmation
Supporting Docs	Retained internally

PRODUCT PHOTO / LABEL EVIDENCE



Visual product reference attached for draft review; exact 30 mg photo should replace before final release.

TESTS REQUESTED AND RESULTS

TEST / PARAMETER	REPORTED RESULT	UNIT / DETAIL	RECORD BASIS
Peptide identity / analyte	Retatrutide	Label claim: 30mg	Supporting documentation retained internally
Reported content / amount	31.05 mg	Transcribed exactly from retained documentation	Internal document-control record
Purity	99.442%	Reported purity	Internal document-control record
Photo / label evidence	Visual product reference attached for draft review; exact 30 mg photo should replace before final release.		

Document control note: This AnalytiLabs record is a formatted documentary verification record created from supporting documentation retained internally. It preserves extracted values and assigns an internal AnalytiLabs/Verification code for traceability. It does not claim that AnalytiLabs independently performed laboratory analysis unless separately supported by original laboratory records.

Release status: Draft only. Supporting documentation, exact product/lot mapping and authorized QA/legal signature are required before official release or publication.

Prepared by AnalytiLabs Document Control
Formatting and transcription review
Date: 02 May 2026

Document Control

Authorized QA / Legal Review
Signature block for final approval
Date: pending

Authorized Review

Traceability
AL-VR-RETATRUTIDE-30MG-
20260502-005
Verification Key:
BLV-RTA30-20260502-
5C56D451



Internal Extract and Release Controls

DRAFT APPENDIX

Private source identifiers are intentionally excluded from this PDF and retained only in the controlled internal traceability map.

CONTROLLED EXTRACT

CUSTOMER-FACING CONTROLLED EXTRACT

AnalytiLabs document code: AL-VR-RETATRUTIDE-30MG-20260502-005

Verification key: BLV-RTA30-20260502-5C56D451

Record status: Draft / QA Hold

Testing ordered: 09 MAR 2026

Sample received: 16 MAR 2026

Analysis conducted: 17 MAR 2026

Product / sample: Retatrutide 30 mg

Analyte / identity: Retatrutide

Label claim: 30mg

Reported amount: 31.05 mg

Reported purity: 99.442%

Photo note: Visual product reference attached for draft review; exact 30 mg photo should replace before final release.

Private source identifiers are excluded from this customer-facing draft and retained only in the controlled internal traceability map.

QA caution: Do not activate this record, add a final release signature, or publish it until supporting documentation, legal/regulatory review, exact product/lot match and authorized document owner approval are completed.